Skip to content
HowShorted

MADRIGAL PHARMACEUTICALS, INC. short interest in 2021

In 2021, MADRIGAL PHARMACEUTICALS, INC.'s disclosed short interest ran from 18.53% of shares outstanding on 15 Jan 2021 to 8.09% on 31 Dec 2021, a change of -10.44 percentage points. The year's high was 18.53% on 15 Jan 2021 and its low 7.87% on 15 Nov 2021, averaging 11.62% across 24 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 24.82 days on 15 Jan 2021. Full history: MADRIGAL PHARMACEUTICALS, INC..

Cite this page
Plain
Wikipedia
BibTeX

By year: 2019 · 2020 · 2021 · 2022 · 2023 · 2024 · 2025 · 2026

Aggregate net short position time series for MADRIGAL PHARMACEUTICALS, INC. in 2021

2021 in figures

Start of year
18.53% (15 Jan 2021)
End of year
8.09% (31 Dec 2021)
Change
-10.44 pp
High
18.53% (15 Jan 2021)
Low
7.87% (15 Nov 2021)
Average
11.62%
Highest days to cover
24.82 (15 Jan 2021)
SEC filings marked
8

Every report in 2021

MADRIGAL PHARMACEUTICALS, INC. short interest in 2021
SettlementShort interestDays to coverFilings since previous
15 Jan 202118.53%24.82
29 Jan 202117.02%9.44
12 Feb 202117.90%10.19
26 Feb 202117.23%20.6210-K filed, results (8-K)
15 Mar 202115.88%18.33
31 Mar 202115.17%18.81
15 Apr 202114.42%17.01
30 Apr 202112.30%22.50
14 May 202112.44%23.6010-Q filed, results (8-K)
28 May 202111.49%12.71
15 Jun 202110.62%9.34
30 Jun 202110.04%7.70
15 Jul 202110.09%10.76
30 Jul 20219.62%15.72
13 Aug 20219.92%18.3410-Q filed, results (8-K)
31 Aug 20219.42%17.25
15 Sep 20218.74%14.64
30 Sep 20218.72%12.50
15 Oct 20218.14%12.65
29 Oct 20218.44%16.45
15 Nov 20217.87%10.8310-Q filed, results (8-K)
30 Nov 20218.04%12.44
15 Dec 20218.66%9.03
31 Dec 20218.09%6.09

See also: MADRIGAL PHARMACEUTICALS, INC.'s full history · most shorted US stocks of 2021 · today's US league.

About this data

US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.